RxDoctor Payments Data

Rong-Bao Lu, MD

Family Medicine · New York, NYNPI 1114029485

Payments from drug & device makers

$488in general payments, 2019–2025

Across 19 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$178
  • GSK$163
  • Amgen$68
  • Idorsia Pharmaceuticals US Inc$33
  • Bayer$18
  • IBSA Pharma Inc.$17
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$488100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic1$178
GSK10$163
Amgen3$68
Idorsia Pharmaceuticals US Inc2$33
Bayer1$18
IBSA Pharma Inc.1$17
AbbVie1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$488 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$88,836
Medicare patients
82
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$10,060
Diclofenac Epolamine16$9,484
VascepaIcosapent Ethyl19$5,288
CreonLipase/Protease/Amylase15$1,756
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth12$1,281
Omega-3 Acid Ethyl Esters20$1,278
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,171
Ammonium Lactate37$942
Halobetasol Propionate13$602
Atorvastatin Calcium94$503
Triamcinolone Acetonide23$495
Alcohol Prep PadsAlcohol Antiseptic Pads14$470
Metoprolol Succinate67$460
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$459
Amlodipine Besylate107$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$11$1,75615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →